PRE-EXPOSURE PROPHYLAXIS FOR SARS-COV-2 INFECTION WITH SUBCUTANEOUS CASIRIVIMAB/IMDEVIMAB IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES.

Fagni F, Schmidt K, Bohr D, Valor L, Hartmann F, Tascilar K, Manger K, Manger B, Kleyer A, Simon D, Schett G, Harrer T (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 968-969

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2022-eular.4266

Authors with CRIS profile

Filippo Fagni Department of Medicine 3 – Rheumatology and Immunology Koray Tascilar Department of Medicine 3 – Rheumatology and Immunology Bernhard Manger Professur für Rheumatologie und Klinische Immunologie Arnd Kleyer Department of Medicine 3 – Rheumatology and Immunology David Simon Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III Thomas Harrer Professur für Innere Medizin mit dem Schwerpunkt Immundefizienz

How to cite

APA:

Fagni, F., Schmidt, K., Bohr, D., Valor, L., Hartmann, F., Tascilar, K.,... Harrer, T. (2022). PRE-EXPOSURE PROPHYLAXIS FOR SARS-COV-2 INFECTION WITH SUBCUTANEOUS CASIRIVIMAB/IMDEVIMAB IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES. In ANNALS OF THE RHEUMATIC DISEASES (pp. 968-969). LONDON: BMJ PUBLISHING GROUP.

MLA:

Fagni, Filippo, et al. "PRE-EXPOSURE PROPHYLAXIS FOR SARS-COV-2 INFECTION WITH SUBCUTANEOUS CASIRIVIMAB/IMDEVIMAB IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2022. 968-969.

BibTeX: Download